[O-33] 一般演題口演セッション33
神経放射線・機能画像・創薬など

[O-33-4] FIREFISH試験：脊髄性筋萎縮症（SMA）I型患者におけるリスジプラムの有効性及び安全性

^○竹島 泰弘¹, Laurent Servais², Giovanni Baranello³, Maria Mazurkiewicz-Beldzinska⁴, Kristy Rose⁵, Dmitry Vlodavets⁶, Hui Xiong⁷, Muna El-Khairi⁸, Sabine Fuerst-Recktenwald⁸, Marianne Gerber⁸, Ksenija Gorni⁸, Heidemarie Kletzl⁸, Renata Scalco⁸, 八木下 知子⁹, Basil T. Darras¹⁰ (1.兵庫医科大学 小児科, 2.Reference Center for Neuromuscular Disease, Centre Hospitalier Régional de La Citadelle, 3.Carlo Besta Neurological Research Institute Foundation, Developmental Neurology Unit, 4.Department of Developmental Neurology, Medical University of Gdansk, 5.Paediatric Gait Analysis Service of New South Wales, The Children’s Hospital at Westmead Sydney, 6.Russian Children Neuromuscular Center, Veltischev Clinical Pediatric Research Institute of Pirogov Russian National Research Medical University, 7.Department of Pediatrics, Peking University First Hospital, 8.F. Hoffmann-La Roche Ltd., 9.中外製薬株式会社, 10.Boston Children’s Hospital, Harvard Medical School)